ScholarIQanswers from OpenAlex & ORCID
Stéphane Oudard
ResearcherPublications, citations & collaboration network
Stéphane Oudard is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stéphane Oudard have?
ScholarIQindexed works
Stéphane Oudard has 1,254 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stéphane Oudard have?
ScholarIQcitation count
Stéphane Oudard has 66,918 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stéphane Oudard?
ScholarIQh-index
Stéphane Oudard has an h-index of 102 in OpenAlex.
What is the i10-index of Stéphane Oudard?
ScholarIQi10-index
Stéphane Oudard has an i10-index of 399 in OpenAlex.
What is the ORCID of Stéphane Oudard?
ScholarIQorcid
The ORCID for Stéphane Oudard is on the source record.
What is the OpenAlex record for Stéphane Oudard?
ScholarIQopenalex
The OpenAlex for Stéphane Oudard is on the source record.
What are the most-cited papers on Stéphane Oudard?
ScholarIQmost cited works
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock, Ronald de Wit, William R. Berry, J Horti, A Płużańska, Kim N., Stéphane Oudard, Christine Théodore, Nicholas D. James, Ingela Turesson, Mark Rosenthal, Mario A. Eisenberger
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann S. de Bono, Stéphane Oudard, Mustafa Özgüroğlu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocák, Gwénaëlle Gravis, I. Bodrogi, Mary J. MacKenzie, Liji Shen, Martin Roessner, Sunil Gupta, Oliver Sartor
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Arnaud Méjean, Alain Ravaud, Simon Thézenas, Sandra Colas, Jean‐Baptiste Beauval, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Hervé Lang, Laurent Guy, Gwénaëlle Gravis, Frédéric Rolland, Claude Linassier, É. Lechevallier, Christian Beisland, Michael Aitchison, Stéphane Oudard, Jean‐Jacques Patard, C Théodore, Christine Chevreau, Brigitte Laguerre, Jacques Hubert, Marine Gross‐Goupil, Jean‐Christophe Bernhard, Laurence Albigès, Marc‐Olivier Timsit, Thierry Lebrét, Bernard Escudier
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, Nobuaki Matsubara, Lajos Géczi, Susanna Cheng, Yves Fradet, Stéphane Oudard, Christof Vulsteke, Rafael Morales‐Barrera, Aude Fléchon, Şeyda Gündüz, Yohann Loriot, Alejo Rodríguez‐Vida, Ronac Mamtani, Evan Y. Yu, Kijoeng Nam, Kentaro Imai, Blanca Homet Moreno, Ajjai Alva, D. Cascallar, Mirta Varela, Mauricio Fernández Lazzaro, Diego Kaen, Gabriela Gatica, David Hugo Flores, Agustín Falco, Matias Molina, F. Van Aelst, Christof Vulsteke, Brieuc Sautois, Jean‐Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sérgio Jobim Azevedo, GISELE LOPES MARINHO, João Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, André P. Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, José Luis Leal, Francisco Francisco, Carolina Ibáñez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Fléchon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross‐Goupil, Stéphane Culine, Yohann Loriot, Gwénaëlle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David G. Pfister, Carsten Ohlman, Michael Stöeckle, Manfred P. Wirth, Anja Lorch, Guenter Niegisch, Peter J. Goebell, Martin Boegemann, Axel S. Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian A. Thomas, Thomas Hoefner, András Telekes, Judit Kósa, János Révész, Gyorgy Bodoky, Tibor Csőszi, András Csejtei, Lajos Géczi, Ágnes Ruzsa, Zsuzsanna Kolonics, József Erfán, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Martin Gore, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Georg A. Bjarnason, Stéphane Oudard, Subramanian Hariharan, Se‐Hoon Lee, John B.A.G. Haanen, Daniel Castellano, Eduard Vrdoljak, Patrick Schöffski, Paul N. Mainwaring, Alejandra Nieto, Jinyu Yuan, Ronald M. Bukowski